Clinical Outcomes According to Baseline Blood Pressure in Patients With a Low Ejection Fraction in the CHARM (Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity) Program

Journal of the American College of Cardiology

Volumn 52, Issue 24, 2008, Pages 2000-2007

  Meredith, Peter A ^a   Östergren, Jan ^b   Anand, Inder ^c   Puu, Margareta ^d   Solomon, Scott D ^e   Michelson, Eric L ^f   Olofsson, Bertil ^d   Granger, Christopher B ^g   Yusuf, Salim ^h   Swedberg, Karl ⁱ   Pfeffer, Marc A ^e   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d ASTRAZENECA R AND D   (Sweden)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f ASTRAZENECA   (United Kingdom)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h McMaster Clinic   (Canada)

ⁱ UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

angiotensin receptor blockers; blood pressure; heart failure

Indexed keywords

CANDESARTAN; PLACEBO;

ADULT; AGED; ARTICLE; DEMOGRAPHY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEALTH PROGRAM; HEART DEATH; HEART EJECTION FRACTION; HEART FAILURE; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AGED; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BLOOD PRESSURE; DIASTOLE; FEMALE; HEART FAILURE; HUMANS; HYPOTENSION; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE VOLUME; SYSTOLE; TETRAZOLES; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 56849099114     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.09.011     Document Type: Article

References (15)

1. Rouleau J.L., Roecker E.B., Tendera M., et al., Carvedilol Prospective Randomized Cumulative Survival Study Group. Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. J Am Coll Cardiol 43 (2004) 1423-1429
2. Gheorghiade M., Abraham W.T., Albert N.M., et al., OPTIMIZE-HF Investigators and Coordinators. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296 (2006) 2217-2226
3. Lee T.T., Chen J., Cohen D.J., and Tsao L. The association between blood pressure and mortality in patients with heart failure. Am Heart J 151 (2006) 76-83
4. Anand I.S., Tam S.W., Rector T.S., et al. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol 49 (2007) 32-39
5. Pfeffer M.A. Blood pressure in heart failure: a love-hate relationship. J Am Coll Cardiol 49 (2007) 40-42
6. Kostis J.B., Shelton B.J., Yusuf S., et al. Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. Am Heart J 128 (1994) 358-364
7. Remme W.J., McMurray J.J.V., Hobbs R., et al., SHAPE Study Group. Awareness and perception of heart failure among European cardiologists, internists, geriatricians and primary care physicians. Eur Heart J 26 (2005) 2413-2421
8. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 46 (2005) e1-e82
9. Dickstein K., Cohen-Solal A., Filippatos G., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10 (2008) 933-989
10. Heart Failure Society of America. Executive summary: HFSA 2006 comprehensive heart failure practice guideline. J Card Fail 12 (2006) 10-38
11. Swedberg K., Pfeffer M., Granger C., et al., Charm-Programme Investigators. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Fail 5 (1999) 276-282
12. Young J.B., Dunlap M.E., Pfeffer M.A., et al., Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators and Committees. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 110 (2004) 2618-2626
13. McMurray J.J., Ostergren J., Swedberg K., et al., CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 362 (2003) 767-771
14. Granger C.B., McMurray J.J., Yusuf S., et al., CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 362 (2003) 772-776
15. McMurray J., Ostergren J., Pfeffer M., et al., CHARM Committees and Investigators. Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity (CHARM) programme. Eur J Heart Fail 5 (2003) 261-270